Canadá - inglés - Health Canada

eugia pharma inc. - meropenem (meropenem trihydrate) - powder for solution - 500mg - meropenem (meropenem trihydrate) 500mg

Malta - inglés - Medicines Authority

rowex ltd newtown bantry, co. cork, , ireland - powder for solution for infusion or injection - meropenem 1000 mg - antibacterials for systemic use

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - meropenem trihydrate - powder for solution for injection - 500mg

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - meropenem trihydrate - powder for solution for injection - 500mg

Armenia - inglés - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

hankook korus pharm co. - meropenem - powder for solution for i/v injection/infusion - 500mg

Malta - inglés - Medicines Authority

anfarm hellas s.a. 4 achaias str. & trizinias 14564 kifissia, attiki, greece - meropenem - powder for solution for infusion or injection - meropenem 500 mg - antibacterials for systemic use

Malta - inglés - Medicines Authority

hospira uk limited - meropenem - powder for solution for infusion or injection - meropenem 500 mg - antibacterials for systemic use

Malta - inglés - Medicines Authority

hospira uk limited - meropenem - powder for solution for infusion or injection - meropenem 1 g - antibacterials for systemic use

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - meropenem trihydrate 1140mg equivalent to meropenem 1000mg;   - powder for injection - 1000 mg - active: meropenem trihydrate 1140mg equivalent to meropenem 1000mg   excipient: sodium carbonate - meropenem-aft is indicated for treatment, in adults and children, of the following infections caused by multiple susceptible bacteria and as empiric therapy prior to the identification of the causative organisms: · lower respiratory tract infections · urinary tract infections, including complicated infections · intra-abdominal infections · gynaecological infections, including postpartum infections · skin and skin structure infections · meningitis · septicaemia · empiric treatment, including initial monotherapy, for presumed bacterial infections in host-compromised, neutropenic patients because of its broad spectrum of bactericidal activity against gram positive and gram-negative aerobic and anaerobic bacteria, meropenem is effective for the treatment of polymicrobial infections.

Israel - inglés - Ministry of Health

neopharm (israel) 1996 ltd - meropenem as anhydrous - powder for solution for inj/inf - meropenem as anhydrous 1000 mg/vial - meropenem - for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.